To the editor

New England Journal of Medicine

Volumn 373, Issue 17, 2015, Pages 1674-1675

  Mufti, Ghulam J ^a   Kulasekararaj, Austin G ^a   Marsh, Judith C W ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE MYELOBLASTIC LEUKEMIA; APLASTIC ANEMIA; ASXL1 GENE; BONE MARROW DEPRESSION; CLONAL HEMATOPOIESIS OF INDETERMINATE POTENTIAL; CYTOGENETICS; DECISION MAKING; DNMT3A GENE; GENE; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LETTER; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; SOMATIC MUTATION; FEMALE; GENETICS; MALE; MUTATION;

ANEMIA, APLASTIC; FEMALE; HEMATOPOIESIS; HUMANS; MALE; MUTATION;

EID: 84944705060     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.101056/NEJMc1509703     Document Type: Letter

References (3)

1. Kulasekararaj AG, Jiang J, Smith AE, et al. Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome. Blood 2014;124:2698-704.
2. Steensma DP, Bejar R, Jaiswal S, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood 2015;126:9-16.
3. Marsh JC, Gupta V, Lim Z, et al. Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia. Blood 2011;118:2351-7.